Corner of Academy

Ioannis Tsakiridis, Sonia Giouleka, Apostolos Mamopoulos, Apostolos Athanasiadis and Themistoklis Dagklis*

Investigation and management of stillbirth: a descriptive review of major guidelines

https://doi.org/10.1515/jpm-2021-0403
Received August 9, 2021; accepted February 1, 2022; published online February 21, 2022

Abstract: Stillbirth is a common and devastating pregnancy complication. The aim of this study was to review and compare the recommendations of the most recently published guidelines on the investigation and management of this adverse outcome. A descriptive review of guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Royal College of Obstetricians and Gynecologists (RCOG), the Perinatal Society of Australia and New Zealand (PSANZ), the Society of Obstetricians and Gynecologists of Canada (SOGC) on stillbirth was carried out. Regarding investigation, there is consensus that medical history and postmortem examination are crucial and that determining the etiology may improve care in a subsequent pregnancy. All guidelines recommend histopathological examination of the placenta, genetic analysis and microbiology of fetal and placental tissues, offering less invasive techniques when autopsy is declined and a Kleihauer test to detect large fetomaternal hemorrhage, whereas they discourage routine screening for inherited thrombophilias. RCOG and SOGC also recommend a complete blood count, coagulopathies’ testing, anti-Ro and anti-La antibodies’ measurement in cases of hydrops and parental karyotyping. Discrepancies exist among the reviewed guidelines on the definition of stillbirth and the usefulness of thyroid function tests and maternal viral screening. Moreover, only ACOG and RCOG discuss the management of stillbirth. They agree that, in the absence of coagulopathies, expectant management should be considered and encourage vaginal birth, but they suggest different labor induction protocols and different management in subsequent pregnancies. It is important to develop consistent international practice protocols, in order to allow effective determination of the underlying causes and optimal management of stillbirths, while identifying the gaps in the current literature may highlight the need for future research.

Keywords: definition; examination; guidelines; history; intrauterine death; investigation; laboratory tests; management; postmortem; stillbirth.

Introduction

Stillbirth is defined as fetal death after a prespecified gestational age and/or fetal weight, both of which have historically lacked uniformity among different countries [1]. It is a common pregnancy complication, occurring in approximately one in 160–200 deliveries per year, despite the advances in obstetric care [2, 3]. Importantly, the vast majority of stillbirths (~98%) occur in low/middle-income countries [4]. Stillbirth has a significant physical and psychological impact on both parents and wide-ranging economic consequences on the health systems and society [5].

The most prevalent risk factors associated with stillbirth include nulliparity, maternal age at either end of the reproductive age spectrum [6], non-Hispanic black race, obesity, co-morbid medical conditions such as pregestational/gestational diabetes [7, 8], hypertensive disorders of pregnancy [9, 10], untreated thyroid disorders [11] and antiphospholipid syndrome, smoking [12], illicit drugs and alcohol use [13], assisted reproduction, multifetal gestation [14, 15], fetal growth restriction [16], vasa previa [17, 18], male fetal sex [19], nutritional factors [20], unmarried status, low maternal education, low socioeconomic status and
previous history of fetal death [21] or other adverse pregnancy outcomes [22].

Over the past several decades, the rate of late and term stillbirth has declined substantially, mainly due to the improvement of antenatal and intrapartum care, the reduction of some modifiable risk factors and the early detection of congenital anomalies followed by prompt management [23]. However, the overall stillbirth rate has remained relatively unchanged, as the incidence of important risk factors, i.e. obesity and advanced maternal age, is rising [24]. Moreover, several reports have indicated that parents receive inconsistent advice regarding management options following stillbirth [25]. Thus, the development and implementation of consistent international algorithms for the investigation, management and prevention of stillbirth may hopefully optimize pregnancy outcomes. The aim of this descriptive review was to synthesize and compare current recommendations from influential guidelines on the investigation and management of stillbirth.

Evidence acquisition

The most recently published guidelines on stillbirth were retrieved and a descriptive review was conducted. In particular, four guidelines were identified from: the American College of Obstetricians and Gynecologists (ACOG) [26], the Royal College of Obstetricians and Gynecologists (RCOG) [27], the Perinatal Society of Australia and New Zealand (PSANZ) [28] and the Society of Obstetricians and Gynecologists of Canada (SOGC) [29]. An overview of the recommendations is presented in Table 1 (investigation of stillbirth) and Table 2 (management of stillbirth). Of note, PSANZ and SOGC provide recommendations only for the investigation of stillbirth, whereas ACOG and RCOG also address the issue of management.

Definition and diagnosis

There is no universally accepted definition for stillbirth; in particular, ACOG, PSANZ and SOGC state that stillbirth is defined as the intrauterine death of a fetus at or beyond 20 completed weeks of gestation or, in case of unknown gestational age, weighing at least 350, 400 and 500 g respectively. On the other hand, RCOG has adopted the definition of the Perinatal Mortality Surveillance Report (CEMACH) according to which stillbirth is defined as “the delivery of a baby with no signs of life known to have died after 24 completed weeks of pregnancy” [30]. Moreover, this medical society points out that real-time ultrasonography is the optimal method for the diagnosis of intrauterine death and should be preferred over auscultation and cardiotocography, as it allows not only the direct visualization of the fetal heart, but also the detection of secondary features, such as hydrops, collapse of fetal skull and maceration [31].

Following the diagnosis of stillbirth, healthcare providers should communicate with the parents at an appropriate isolated place, explain their choices regarding the investigation and the mode of delivery and provide emotional support, individualized bereavement care as well as written information (ACOG, RCOG, PSANZ). A prospective study of 808 families who suffered a stillbirth showed that parental choices vary widely and, thus, clinicians should provide personalized care based on their preferences [32].

Investigation

There is an overall consensus among the reviewed guidelines that a thorough investigation is warranted, when stillbirth occurs, in order to identify the underlying cause, ensure appropriate management of any potentially life-threatening maternal disease, determine the chance of recurrence and avoid further pregnancy complications. This investigation should include a structured personal, obstetric and family medical history of the mother, physical examination, laboratory tests, genetic analysis of the fetal and the placental tissues, gross and histological examination of the placenta and postmortem examination of the baby.

Medical history

All the guidelines highlight the importance of taking a detailed maternal medical history in order to determine the etiology of stillbirth, including a history of thromboembolic disorders, diabetes mellitus, hypertensive and autoimmune diseases, known thyroid dysfunction and cyanotic heart disease. Several epidemiological studies support this approach. Thus, a retrospective study of 913,255 pregnancies concluded that women with pregestational and gestational diabetes mellitus have an increased prevalence of intrauterine fetal death (Odds Ratio-OR: 4.197 and 2.511, respectively) [33]. Another cohort study of 1,419 singleton pregnancies found that a preconception history of venous thromboembolism is associated with increased risk of placenta-mediated complications, including stillbirth [34].
### Table 1: Summary of recommendations on the investigation of stillbirth.

|                  | ACOG                      | RCOG                      | PSANZ                      | SOGC                      |
|------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| **Country**      | United States             | United Kingdom            | Australia and New Zealand | Canada                    |
| **Issued**       | March 2020                | October 2010              | January 2020              | January 2020              |
| **Title**        | Obstetric care consensus: management of stillbirth | Late intrauterine fetal death and stillbirth. Green-top guideline no. 55 | Clinical practice guideline for care around stillbirth and neonatal death | Clinical practice guideline no. 394-stillbirth investigation |
| **Pages**        | 23                        | 33                        | 301                       | 8                         |
| **References**   | 139                       | 176                       | 380                       | 79                        |
| **Definition**   | Delivery of a fetus at or beyond 20 weeks of gestation or ≥350 g with no signs of life | Intrauterine fetal death after 24 completed weeks of pregnancy | Intrauterine fetal death after 20 completed weeks of pregnancy at least 400 g birthweight | Intrauterine fetal death after 20 completed weeks of pregnancy or weighing >500 g. |
| **Ideal method for the diagnosis of stillbirth** | Not discussed | Real-time ultrasound. Second opinion if possible. | Not discussed | Not discussed |
| **Best practice for discussing the diagnosis** | Emotional support for the mother, the partner and the family. Good communication. Shared decision making. | Ask the mother to call for company. Explain choices. Provide written information as well. | Ask the mother to call for company. Emotional support. Appropriate place. Good communication. Shared decision making. Provide written information | Not discussed |
| **Investigation** | Recommended | Recommended | Recommended | Recommended |
| **Detailed history (personal, obstetric and family)** | Recommended, including three-generation pedigree | Recommended | Recommended | Recommended |
| **Clinical examination** | Recommended | Recommended | Recommended | Not discussed |
| **Blood tests 1. Complete blood count** | Not discussed. Indirect coombs in selected cases | Recommended | Recommended | Not discussed |
| **Blood tests 2. Blood group** | Not discussed | Not discussed | Recommended | Recommended |
| **Blood tests 3. Coagulation tests** | Not discussed | Not discussed | Recommended (including plasma fibrinogen) | Recommended |
| **Blood tests 4. Thyroid function tests** | Not discussed | Recommended (TSH, FT3, FT4) | Not recommended in the absence of clinical signs | Recommended in case of massive placental abruption or IUD >4 weeks |
| **Blood tests 5. Biochemistry** | Glucose screening is recommended in LGA | Recommended, including CRP, bile salt, random blood glucose (for occult DM), HbA1c (for GDM) | HbA1c (FPG/OGTT) if LGA or SGA. Bile acids and liver enzymes if suspected cholestasis (pruritus) | HbA1c. Bile acids and liver enzymes if suspected cholestasis. |
| **Blood tests 6. Kleihauer test** | Recommended | Recommended | Recommended | Recommended |
| **Blood tests 7. Hemoglobin electrophoresis** | Not discussed | Not discussed | Not discussed | Recommended |
| **Maternal serology for viral screen (TORCH, Parvo B19), syphilis, tropical infections, Listeria** | TORCH not recommended. Testing for syphilis is recommended | Recommended for occult infection | Recommended if SGA/FGR or infection suspected by maternal history/autopsy/placental findings. Parvo in case of hydrops or anemia | Recommended when infection is suspected |
| Test Type                                                                 | ACOG          | RCOG                                      | PSANZ          | SOGC          |
|--------------------------------------------------------------------------|---------------|-------------------------------------------|----------------|----------------|
| Maternal bacteriology (blood cultures, midstream urine, vaginal and cervical swabs) | Not discussed | Recommended in case of fever, flu symptoms, abnormal liquor, prolonged ROM before stillbirth | Not discussed | Not discussed |
| Fetal and placental microbiology (blood and swabs)                       | Recommended (GBS, Listeria, E. Coli and syphilis) | Recommended in case of suspected infection if history/presentation is suggestive | Recommended in case of suspected infection | Recommended (GBS, Listeria, E. Coli) |
| Maternal urine for illicit drug use                                       | Recommended if history/presentation is suggestive | Recommended if maternal history is suggestive | Not recommended for inherited thrombophilia in the absence of other indications. Recommended for APS if personal or family history of thrombosis, SGA/FGR, placental abruption or infarction | Recommended according to maternal condition |
| Maternal thrombophilia screen – Testing for lupus anticoagulant, anticardiolipin antibodies, anti β2-glycoprotein I antibodies | Recommended if evidence of fetal growth restriction or placental disease. | Recommended if evidence of fetal growth restriction or placental disease. | Recommended if evidence of fetal growth restriction or placental disease. | Recommended if evidence of fetal growth restriction or placental disease. |
| Anti-red cell antibody serology                                           | Not discussed | Recommended in case of fetal hydrops, anemia or jaundice | Not discussed | Not discussed |
| Maternal anti-Ro and anti-La antibodies                                  | Not discussed | Recommended in case of hydrops, endomyocardial fibro-elasticity or AV node calcification at postmortem | Not discussed | Not discussed |
| Maternal alloimmune anti-PLT antibodies                                  | Not discussed | Recommended if fetal intracranial hemorrhage at postmortem | Not discussed | Not discussed |
| Parental blood for karyotype                                             | Not discussed | Recommended in case of fetal unbalanced translocation, other fetal aneuploidy, fetal genetic testing fails and history suggestive of aneuploidy (fetal abnormality on postmortem, previous unexplained IUFD, recurrent miscarriage) | Not discussed | Not discussed |
| Fetal and placental tissues for karyotype                                | Recommended, using microarray analysis, especially when guided by clinical history and detected fetal abnormalities. Only with parents' written consent. | Search for aneuploidy and single gene disorders. Use multiple tissue samples. Only with parents' written consent. | Recommended, using microarray analysis if available. Only with parents' written consent. | Recommended, especially if evidence of congenital malformation, IUGR, hydrops, ambiguous genitalia or dysmorphic features. Only with parents' written consent. |
| Determination of baby's gender                                           | Not discussed | Examination of external genitalia by two healthcare practitioners. If doubt, rapid karyotyping with PCR or FISH | Recommended in case of autopsy | Microarray or QF-PCR Not discussed |
| Procedure                                                                 | ACOG                                      | RCOG                                      | PSANZ                                      | SOGC                                      |
|---------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Placental gross and histological examination (plus membranes and cord)    | Recommended when postmortem examination of the baby is declined, by a trained pathologist. | Recommended when postmortem examination of the baby is declined by a specialist perinatal pathologist. | Recommended when maternal and fetal indications are present | Recommended by a specialist perinatal pathologist. Offer virtual autopsy if parents decline a complete fetal autopsy. Histology |
| Postmortem examination (autopsy)                                          | Recommended only with parents’ written consent. Weight, length and head circumference measurements. External examination for dysmorphic features. Photographs. Fetal whole-body X-rays. | Recommended only with parents’ written consent, by a specialist perinatal pathologist. Seek for correlation with blood tests. Weight and length measurement, external examination, histology and X-rays. | Recommended, with parents’ written consent or coroner-mandated, by a specialist perinatal pathologist. A detailed maternal history should accompany the baby. Offer less invasive autopsy if full autopsy is declined. Photographs, Internal and external examination, X-rays, Histology |                                      |
| Postmortem ultrasound and MRI                                             | Indicated when autopsy is declined, along with sampling of tissues, gross examination, photographs and X-rays | Not recommended as a routine. MRI only as an adjunctive tool. | Indicated when autopsy is declined, along with needle biopsy of specific internal organs, external examination of the body, X-rays or laparoscopic autopsy | Indicated when autopsy is declined, along with needle biopsy of specific internal organs, external examination of the body with X-ray and CT |

ROM, rupture of membranes; CRP, C-reactive protein; DIC, disseminated intravascular coagulation; GDM, gestational diabetes mellitus; TORCH, toxoplasma, rubella, CMV, herpes simplex; QF-PCR, quantitative fluorescence polymerase chain reaction; FISH, fluorescence in situ hybridization; GBS, Group-B Streptococcus; LGA, large for gestational age; SGA, small for gestational age; APS, antiphospholipid syndrome; MRI, magnetic resonance imaging.
### Table 2: Summary of recommendations on the management of stillbirth.

| Management of rhesus D-negative women with stillbirth | ACOG | RCOG |
|------------------------------------------------------|------|------|
| Management of rhesus D-negative women with stillbirth | Kleihauer test | Kleihauer test. Administration of RhD immunoglobulin as soon as possible. Increased dosage if large FMH. Repeat Kleihauer test at 48 h. Type the baby’s blood type (cfDNA or serology on cord blood) |
| Indications for immediate delivery | Not discussed | Sepsis, preeclampsia, placental abruption/bleeding, membrane rupture, laboratory evidence of DIC |
| Expectant management | Consider as coagulopathies associated with prolonged fetal retention are uncommon. | Consider if no indications for immediate delivery exist. Blood tests twice weekly (for DIC) if delay >48 h. Consider amniocentesis for cytogenetic results |
| Management of women with unscarred uterus | Induction of labor is preferred. Alternatively, dilation and evacuation can be offered in the 2nd trimester. Cesarean should be reserved for unusual circumstances. | Vaginal birth is recommended. Consider cesarean in case of maternal wish/condition. |
| Induction of labor | <28 weeks: Misoprostol vaginally (or orally), 400–600 μg every 3–6 h +/- mifepristone 24–48 h earlier. High-dose oxytocin is also acceptable. >28 weeks: Usual obstetric protocol | Mifepristone and prostaglandin (E1-Misoprostol is preferred over E2, vaginally over orally) |
| Management of women with a history of lower segment cesarean section (LSCS) | <28 weeks: Insufficient data to guide clinical practice for the optimal dose and route of administration of misoprostol. >28 weeks: Induction of labor as per standard obstetric protocols for VBAC (+/- transcervical Foley catheter for cervical ripening). Cesarean is a reasonable option. | Advise labor induction for women with up to two LSCS (with mifepristone alone or low-dose misoprostol). Monitor for features of scar rupture. Oxytocin augmentation should be decided by a consultant obstetrician. |
| Management of women with atypical uterine scars or >2 LSCS | Not discussed | Insufficient data to guide clinical practice |
| Intrapartum antimicrobial therapy | Not discussed | Not recommended as a routine. Broad-spectrum antibiotics in case of sepsis. Intrapartum antibiotics for GBS colonized women are not indicated. |
| Pain relief during labor | Not discussed | Diamorphine over pethidine. Regional anesthesia is recommended (assess for DIC and sepsis before) |
| Postnatal thromboprophylaxis | Not discussed | Recommended if risk factors are present (IUD is not considered a risk factor). Hematologist consultation in case of DIC. |
| Lactation suppression | Not discussed | Dopamine agonists are recommended (cabergoline over bromocriptine) unless preeclampsia or hypertension is present. Avoid non-pharmacological measures and estrogens. |
| Counseling and bereavement Subsequent pregnancy | Recommended If previous stillbirth ≥32 weeks, once or twice weekly antenatal surveillance is recommended at 32 weeks or starting 1–2 weeks before the gestational age of previous stillbirth. If previous stillbirth <32 weeks, individualized antenatal care. | Recommended Obstetric antenatal care and screening for GDM are recommended. If stillborn baby was SGA, serial US for fetal growth is recommended. |
and a study of 135,466 pregnant women showed that women with any hypertensive disorder are 1.4 times more likely to have a stillbirth [35]. Moreover, symptoms of intrahepatic cholestasis of pregnancy (i.e. pruritus) should be recorded, as a meta-analysis concluded that severe cholestasis of pregnancy (total bile acids ≥100 μmol/L) is associated with increased risk of stillbirth compared to controls (Hazard Ratio: 30.5; 95% Confidence Interval-CI: 8.83–105.30) [36]. In addition, a careful documentation of antepartum hemorrhage or infection, as well as previous adverse pregnancy outcomes, are required to facilitate investigation; this statement is based on a systematic review and meta-analysis which proved that the risk of stillbirth in subsequent pregnancies is higher in women who experience a stillbirth in their first pregnancy (OR: 4.83; 95% CI: 3.77–6.18) [21] and on a retrospective cohort study which showed that complicated first births of live-born infants are associated with an increased risk of unexplained stillbirth in the next pregnancy [22]. Finally, questions regarding familial disorders, inherited conditions and consanguinity should never be omitted as they can also unveil potential causes of stillbirth.

Clinical examination

There is an agreement among all the medical societies that clinical examination of the mother is an integral part of stillbirth’s investigation. Clinicians should evaluate maternal weight and blood pressure and seek for signs of preeclampsia, chorioamnionitis, placental abruption, abdominal trauma, thyroid disease and substance use (ACOG, RCOG, SOGC).

Laboratory tests

The RCOG and the SOGC guidelines agree that a complete blood count along with maternal coagulation studies (including plasma fibrinogen levels) should be performed in case of stillbirth, in order to detect potential complications of preeclampsia and disseminated intravascular coagulation (DIC). The latter is more likely to occur in case of massive placental abruption, maternal sepsis, preeclampsia and expectant management of an intrauterine death of more than 4 weeks [37]. Thus, RCOG recommends testing for DIC twice a week for women who decide to delay labor more than 48 h.

With regards to the determination of the maternal blood group, PSANZ and SOGC point out that if it was not performed antenatally as a routine, it is crucial to be performed.
after the diagnosis of stillbirth to exclude hemolytic disease of the fetus due to maternal sensitization to red cell antigens [38]. RCOG and PSANZ also recommend anti-red cell antibody screening in case of fetal anemia, hydrops or jaundice.

There is no agreement on the necessity of thyroid function tests as part of stillbirth’s investigation; RCOG recommends measuring maternal TSH, FT3 and FT4 levels in all women with late stillbirth in order to rule out occult thyroid disease. On the other hand, PSANZ and SOGC state that routine thyroid testing in the absence of clinical signs of thyroid dysfunction is not justified, as a multicenter prospective cohort study of 1,025 women found no strong association of subclinical thyroid disease with stillbirth and no beneficial effect of treating them with levothyroxine [39].

Likewise, maternal glucose screening is a matter of controversy. The RCOG and the SOGC guidelines favor routine measurement of HbA1c in case of intrauterine growth restriction (IUGR) and/or stillbirth, while ACOG and PSANZ guidelines are against this strategy and recommend screening for diabetes mellitus only in cases of fetal growth restriction and large or small for gestational age (SGA) fetuses. The latter statement is based on a prospective cohort study, which found that diabetes causes stillbirth in less than 0.5% of cases and, thus, routine testing is not necessary [40].

Three of the reviewed guidelines (RCOG, PSANZ, SOGC) highlight that, following a stillbirth, liver function and bile acid testing is required when obstetric cholestasis is suspected, i.e. when the patient reports pruritus during pregnancy [41].

Moreover, according to all medical societies, the performance of Kleihauer-Betke test to all women with stillbirth, irrespective of their RhD type, is necessary in order to detect large feto-maternal hemorrhage (FMH) and should preferably be performed antenatally (RCOG, PSANZ) as fetal red cells might clear from maternal circulation immediately after birth. In a multicenter prospective cohort study of 1,025 fetal deaths at or beyond 20 weeks of gestation, an abnormal Kleihauer-Betke was noticed in 11.9% of cases [40]. In addition, a cross-sectional study of 192,132 non-anomalous infants found that FMH accounted for 4.1% (34/828) of antepartum stillbirths [42].

Notably, the SOGC recommends hemoglobin electrophoresis assessment in case of fetal hydrops, maternal anemia or possible a-thalassemia, as part of stillbirth investigation.

Serology

Several discrepancies were detected regarding the indications of maternal serology testing for viral infections and syphilis. In particular, ACOG, PSANZ and SOGC do not recommend routine testing for toxoplasmosis, rubella, cytomegalovirus (CMV) and herpes simplex virus (TORCH), based on a retrospective study of 745 stillbirths, which found no obvious benefit from congenital infection screening in the evaluation of such cases [43]. More specifically, SOGC mentions that serology for TORCH, Parvovirus B19 and Listeria should be performed only when the infection is clinically suspected and PSANZ supports a targeted investigation based on maternal history, SGA fetuses, autopsy and placental findings. Although CMV infection in pregnancy is strongly associated with stillbirth, it can be also randomly discovered [44]; targeted screening in case of placental histopathological evidence or SGA fetus is justified (PSANZ). Regarding toxoplasmosis, a systematic review concluded that it is not a common cause of stillbirth [45], rendering its routine testing unreasonable (PSANZ). Moreover, as Parvovirus B19 disease is apparent in the examination of the baby and/or the placenta when causing stillbirth, PSANZ recommends testing for this infection only in case of severe fetal anemia and/or non-immune hydrops [40, 46]. As for rubella and syphilis, if the initial antenatal screening was omitted, routine testing as part of stillbirth investigation is not recommended in the absence of specific indications, as they are both rare infections in high-income countries [46].

On the contrary, RCOG is in favor of routine maternal serology testing for TORCH, syphilis and Parvovirus B19, claiming that this strategy may reveal occult infections that can result in stillbirth. This recommendation is based on a prospective case-control study which proved that there is statistically significant correlation between viral infections and stillbirth, especially in advanced gestational age [47]. In addition, a multicenter study of 14,147 deliveries in Sweden concluded that the sensitivity of conventional diagnostic procedures for stillbirth could be greatly improved by addition of Parvovirus B19 PCR, as its presence in cases of late second- and third-trimester fetal death is relatively common [48].

Bacteriology (blood cultures, midstream urine, vaginal and cervical swabs)

According to RCOG, clinicians should offer maternal blood cultures, midstream urine culture and/or vaginal and cervical swabs when bacterial infection is suspected, i.e. when stillbirth is accompanied by maternal fever, flu-like symptoms, abnormal vaginal liquor or prolonged rupture of membranes. However, it is stated that abnormal results are of doubtful importance in the absence of clinical or
histological signs of chorioamnionitis, as a retrospective study failed to find a statistically significant association between positive cervicovaginal culture and stillbirth [49]. Of note, the other medical societies do not make any relevant recommendation.

**Fetal and placental microbiology**

There is an overall agreement that fetal and placental specimens (blood or swabs) should be tested for potential fetal infections that could result in stillbirth, as it has been showed that up to 24% of cases can be infection-related stillbirths [50]. Moreover, a case control study of placentas from 66 stillbirths and 66 term live births found that chorioamnionitis occurred 2.6 times more often in women with stillbirths than in women with live births [51]. RCOG points out that fetal tissues are more reliable and informative than maternal ones for the detection of viral infections. ACOG and SOGC recommend routine testing for group B Streptococcus (GBS), Listeria, Escherichia Coli and Syphilis, as these are the most common pathogens, while other bacterial cultures should be considered only if clinically indicated. A systematic review and meta-analysis of 14 studies concluded that 1% of all stillbirths in developed countries and 4% in Africa are associated with GBS [52]. On the other hand, the PSANZ guideline supports a more targeted investigation when infection is suspected [40, 46].

**Maternal urine testing for illicit drug use**

All the guidelines agree that testing for substance use following stillbirth should be considered when maternal history or presentation is suggestive; a case-control study showed that smoking, exposure to second-hand smoke and illicit drug use, separately or in combination during pregnancy, are associated with an increased risk of stillbirth [53]. The ACOG adds placental abruption as an indication for toxicology screening, based on two studies that proved its significant correlation with cocaine use and cigarette smoking [54, 55].

**Thrombophilia screening**

Screening for inherited thrombophilia as part of stillbirth’s investigation is unanimously not recommended; to date, there is no robust evidence to convincingly support the association between otherwise unexplained intrauterine fetal death and positive thrombophilia screening [56]. ACOG mentioned that it should only be considered in case of personal or family history of thromboembolic disease [57]. On the other hand, testing for antiphospholipid syndrome, which is a type of acquired thrombophilia, by measuring lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies is recommended as a routine (ACOG, SOGC) or in case of fetal growth restriction, SGA, placental disease (RCOG, PSANZ) and family or personal history of thrombosis (PSANZ) [58]. A multicenter case-control study found a three- to five-fold increased odds of stillbirth when anticardiolipin and anti-β2-glycoprotein I antibodies are elevated [59]. Moreover, a systematic review and meta-analysis showed that there is a strong association between positive lupus anticoagulant and late fetal loss in antiphospholipid syndrome patients [60].

**Testing for autoimmune diseases (anti-Ro and anti-La antibodies)**

The RCOG and SOGC guidelines recommend the measurement of maternal anti-Ro and anti-La antibodies, when investigating stillbirth accompanied by fetal hydrops, endomyocardial fibro-elastosis or AV node calcification at postmortem examination. A meta-analysis concluded that systemic lupus erythematosus increases the risk of stillbirth [61]. Of note, the other guidelines do not make any relevant recommendation.

**Testing for alloimmune thrombocytopenia**

According to RCOG alone, fetal intracranial hemorrhage found on postmortem examination is an indication for maternal alloimmune thrombocytopenia testing by measuring antiplatelet antibodies’ levels [62].

**Parental blood karyotype**

Chromosome testing of both parents for mosaicism or balanced translocation is indicated in case of recurrent miscarriages and stillborn fetuses with congenital malformations or dysmorphic features reported on postmortem examination (RCOG, SOGC). This statement is based on a study of 77 couples with no apparent cause for recurrent spontaneous abortion, which found that the incidence of chromosomal abnormalities was 7.79% compared to 2.6% in the general population and, thus, supports parental
As chromosomal abnormalities are present in about 6–13% of all stillbirths [40, 65], karyotypic analysis of fetal and placental tissues is recommended by all the reviewed guidelines, in terms of unexplained stillbirth investigation. More specifically, after parents’ written consent, samples from the fetal skin or cartilage and the fetal surface of the placenta should be obtained, kept in culture fluid with antibiotics, in order to avoid contamination with bacteria (RCOG) and sent for cytogenetic analysis. Alternatively, invasive testing, i.e. amniocentesis, can be performed before delivery, when expectant management is chosen, as the amniotic fluid has the highest yield for fetal karyotyping. This statement is based on a study of 230 samples from stillbirth cases which found a that invasive testing was superior to solid tissue testing in successful karyotyping [66]. The ACOG, SOGC and PSANZ guidelines point out that chromosomal microarray analysis (CMA) should be preferred over conventional karyotyping, as a systematic review and meta-analysis showed that this technique provides better detection of genetic abnormalities, improves the test success rate and thus, is more likely to set the diagnosis of stillbirth for the purpose of counseling on future pregnancies [67]. Moreover, ACOG and SOGC mention that the performance of fetal karyotyping is of greater importance and higher diagnostic yield in cases with congenital malformations, fetal dysmorphic features, hydrops, ambiguous genitalia and fetal growth restriction [68].

Of note, only RCOG refers to the determination of baby’s sex; it highlights the difficulty and doubt that occur frequently, even after the inspection of external genitalia by two experienced healthcare providers, especially when the baby is hydropic, macerated or extremely preterm. In such cases, the performance of rapid karyotyping using quantitative fluorescent PCR or fluorescence in situ hybridization (FISH) is recommended [69].

**Gross and histological examination of the placenta, the fetal membranes and the umbilical cord**

Irrespective of full or limited autopsy, the meticulous gross and microscopic examination of the placenta along with the fetal membranes and the umbilical cord is an essential parameter of stillbirth investigation recommended by all the reviewed guidelines. It provides useful information regarding the cause of fetal death and the chorionicity of multifetal gestations and may reveal conditions such as placental abruption, infarcts, calcifications, hematomas, infection, preeclampsia, growth restriction, umbilical cord thrombosis, true knots, genetic abnormalities, velamentous cord insertion and vascular malformations [26, 29]. A systematic review supported the utility of the histopathological examination of the placenta as it found that the proportion of stillbirths attributed to placental causes ranges from 11 to 65% [70]. Moreover, a multicenter prospective cohort study of 1,025 fetal deaths at or beyond 20 weeks of gestation showed that placental examination was abnormal in 89.2% (95% CI: 87.2–91.1) of cases [40].

PSANZ mentions certain maternal, fetal and placental indications for the histopathological examination of the placenta, including preeclampsia, systemic maternal disorders, suspected infection or chorioamnionitis, preterm delivery either spontaneous or iatrogenic, stillbirth, fetal hydrops and anemia, abnormal placental or umbilical cord size, amniotic fluid abnormalities and placental abruption.

Notably, the ACOG guideline underlines that the finding of umbilical cord entanglement is insufficient evidence to explain stillbirth. This is based on a cohort study of 13,757 deliveries (including 98 stillbirths), which reported that a single nuchal cord encirclement was a very common finding, observed in 23.6% of deliveries and that multiple encirclements were found in 3.7% of them; importantly, no association with increased risk for stillbirth was identified (OR: 1.029; 95% CI: 0.64–1.6) [71].

**Postmortem examination**

There is an overall consensus that postmortem examination is one of the core investigations when trying to determine the accurate cause of stillbirth and thus, it is strongly recommended. A systematic review found that autopsy revealed a change in diagnosis or additional findings in 22–76% of cases [72]. Another study showed
that fetal autopsy is useful in identifying causes of death in 42.4% (95% CI: 36.9–48.4) of cases [73]. This examination may additionally exclude some potential causes of death, identify disorders that may implicate subsequent pregnancies, guide counseling in order to prevent recurrence, assist the bereavement care by helping the parents understand the underlying pathology and alleviate feelings of guilt [2, 28, 74]. A written informed consent by the parents is required even for minimally invasive procedures, allowing at the same time free choice and respecting cultural, religious and individual beliefs. A specialist perinatal pathologist should undertake the postmortem examination (RCOG, PSANZ), which should include external examination of the baby for dysmorphic features or structural anomalies, measurement of length, weight and head circumference, whole-body X-rays, photographs (ACOG, RCOG, PSANZ), histological examination of internal organs (RCOG, PSANZ) and tissue sampling for microbiological analysis [75].

All the reviewed guidelines agree that when parental consent for conventional autopsy is withheld, less invasive procedures should be offered. These procedures may include tissue sampling with needle biopsy of specific internal organs, gross examination, full-body X-rays, photographs, postmortem magnetic resonance imaging (MRI), ultrasound and/or computerized tomography scan of the baby. The PSANZ also suggests the laparoscopic approach as an alternative option for obtaining internal organ samples. In a prospective study, minimally invasive autopsy was found to have accuracy similar to that of traditional autopsy for the detection of death cause or major pathological abnormality after death in fetuses, newborns and infants, although being less accurate in older children [76]. In addition, a retrospective analysis of radiographic images from 2,032 stillbirths and second trimester losses showed that radiographs yielded a diagnosis in 45% of the infants with abnormalities and were crucial in setting a diagnosis that would otherwise be missed or incomplete in 1.5% of the total infants [77].

However, RCOG points out that MRI should not be used as a substitute of conventional autopsy, but only as an adjunctive tool. This recommendation is based on a retrospective study of 100 stillborn fetuses that underwent both postmortem MRI and autopsy, which found that in 54 of them there was complete agreement between the MRI and autopsy findings, in 24 the MRI added valuable information to the autopsy, but, in 17 of 24 cases (71%), if MRI had been the only investigation, essential information would have been lost [78].

Management

Recommendations for Rhesus D-negative women

All medical societies recommend the performance of Kleihauer-Betke test to all women who experience stillbirth. Moreover, RCOG points out this test must be undertaken urgently after an stillbirth diagnosis in order to timely detect an FMH and subsequently administer anti-RhD immunoglobulin within 72 h from the sensitizing event; the dosage should be increased in case of a large FMH [79]. If the Kleihauer test remains positive, the baby’s blood group should be typed, either by conventional serology on umbilical cord blood or by free fetal DNA from maternal blood with the intention of making a differential diagnosis between a large FMH and a RhD negative baby.

Indications for immediate delivery after stillbirth – expectant management

According to the RCOG, following an intrauterine death, delivery should be expedited if there are signs of pre-eclampsia, sepsis, placental abruption or membrane rupture and if the laboratory tests are suggestive of DIC. Otherwise, expectant management may be considered for a short-term period, as the risk for coagulopathies and infections for up to 48 h is low (ACOG, RCOG) [80]. However, in the majority of cases (85–90%), spontaneous delivery occurs within three weeks from the fetal demise [81]. If postponement of delivery is decided for a period longer than 48 h from diagnosis, the RCOG recommends testing for DIC twice a week, as already mentioned. Moreover, the mother should be informed that this strategy reduces the diagnostic yield of postmortem examination.

Management of women with unscarred uterus

There is agreement between ACOG and RCOG that induction of labor (IOL) is the recommended method of delivery of a stillborn fetus [82], although ACOG also suggests the dilation and evacuation as an alternative for second trimester intrauterine deaths. Vaginal birth has the advantage of shorter convalescence period compared to cesarean delivery and provides the ability to preserve the baby and detect
dysmorphic features on postmortem examination compared
to dilation and evacuation. Importantly, it can be accom-
plished within 24 h of IOL in 87.5% of stillbirth cases [83]. On
the other hand, it is correlated with an increased risk of
placenta retention and need for curettage, especially in the
early second trimester (ACOG). In addition, a retrospective
cohort study of cases with a fetal demise concluded that IOL
is significantly associated with increased maternal
morbidity, as a result of higher odds of infection requiring
intravenous antibiotics, while dilation and evacuation is
probably a safer approach (OR: 5.36; 95% CI: 2.46–11.69) [84].

Both guidelines (ACOG, RCOG) support that cesarean
delivery may sometimes be considered depending on
maternal wish and medical condition, always taking into
consideration the increased risk of maternal complications
and the absence of fetal benefit following this approach.

Methods for induction of labor

Regarding the appropriate method for IOL in case of still-
birth, both the ACOG and the RCOG guidelines suggest the
vaginal administration of misoprostol, based on a sys-
tematic review, which proved the efficacy of this regimen
in the second and third trimester [85]. A meta-analysis of 14
randomized controlled trials showed that among women
with a stillbirth, both vaginal and oral misoprostol are
highly effective in achieving uterine evacuation within
48 h, although the latter is more effective within the first
24 h [86]. In addition, combination of different routes of
misoprostol (i.e. vaginal-sublingual/vaginal-oral) have
been proven to be effective for the second trimester fetal
demise [87]. Mifepristone could be considered as an
adjunct to misoprostol given at a single dose of 200 mg 24–
48 h before IOL in women with stillbirth as it reduces the
induction-to-delivery interval by 7 h compared to other
regimens (ACOG, RCOG) [83].

RCOG points out that misoprostol, which is a prosta-
glandin E1 analog, should be preferred over prostaglandin
E2 as many studies have proven that these two prosta-
glandins demonstrate equally efficient and safe profile, but
misoprostol costs significantly less, has fewer side-effects
and is easier to store [88, 89]. The optimal dosage of
misoprostol and the frequency of administration have not
been ascertained to date. RCOG recommends adjustment of
dose according to the gestational age (from 25 to 100 μg
every 4–6 h), while ACOG suggests a dose of 400–600 μg
every 3–6 h.

Of note, ACOG mentions that high-dose of oxytocin
infusion may be a safe alternative to a combined
mifepristone-misoprostol treatment and that stillbirths
occurring beyond 28 weeks of gestation should be
managed according to usual obstetric protocols.

Management of women with a history of
lower segment caesarean section (LSCS)

There is an overall agreement between ACOG and RCOG
that IOL is a safe option for women with one previous
hysterotomy and thus, should be preferred in case of fetal
demise, as the most frequent severe risks of VBAC relate
to the fetus [90]. A retrospective study of 611 stillbirths
showed that IOL resulted in vaginal birth in 91% of women
with a history of prior caesarean section with only two
cases of uterine rupture [91]. However, they suggest a
modified management of such women compared to those
without previous hysterotomy.

The RCOG recommends the use of mifepristone alone
or the administration of misoprostol in lower doses, close
monitoring for features of uterine scar rupture and caution
in the use of oxytocin augmentation. Nevertheless, there
are no available studies on the efficacy and safety of IOL
with misoprostol or oxytocin augmentation following
stillbirth in women with an LSCS history. The RCOG also
underlines that mechanical methods for IOL should be
avoided in the context of previous LSCS history because,
although safe and effective in achieving birth, they are
associated with increased risk of ascending infection in
case of fetal demise [92]. Women with two previous ce-
sarean deliveries should also be advised to attempt IOL
instead of cesarean delivery, according to the RCOG, as a
history of multiple cesarean deliveries is not associated
with an increased rate of uterine rupture in women
attempting vaginal birth (0.9%) compared with those with
a single prior operation (0.7%) [93]. Finally, for those pa-
tients with three or more cesarean sections as well as
those with atypical uterine scars, RCOG states that there is
inadequate evidence to recommend for or against IOL in
cases of stillbirth.

On the other hand, the ACOG differentiates the rec-
ommendations based on the gestational age; for stillbirths
occurring before 28 weeks of gestation, it mentions that
there is insufficient data regarding the safety, the efficacy,
the ideal regimen and the optimal route of administration,
although a case-control study of 108 women with a previ-
ous cesarean delivery and 216 women without such a his-
tory failed to prove that a previous cesarean affects the
incidence of complications when undergoing a mid-
trimester pregnancy termination with misoprostol [94].
For stillbirths beyond 28 weeks of gestation, ACOG rec-
ommends IOL as per standard obstetric protocols for
vaginal birth after previous cesarean delivery. Contrary to the RCOG, ACOG recommends the use of Foley catheter for cervical ripening in patients with low Bishop score after 28 weeks and a history of previous hysterotomy; a retrospective study concluded that IOL using a transcervical Foley catheter is not associated with an increased risk of uterine rupture, although having lower rate of success in achieving vaginal birth after cesarean delivery [95].

**Intrapartum antibiotic therapy and pain relief**

RCOG recommends against routine antibiotic prophylaxis during labor even for group B streptococcus positive women, as this strategy primarily aims to protect the neonate from infection. However, in case of maternal sepsis, intravenous broad-spectrum antibiotics, including anti-chlamydial agents, should be administered, as the stillborn fetus can become a focus of severe secondary infections resulting in DIC, irrespective of the primary cause of death.

With regards to intrapartum analgesia, it is crucial that is offered to all parturients with stillbirth (RCOG). This statement is based on a population-based cohort study of 314 women with stillbirth and 322 women with live births which showed that delivery was harder and less sufferable for women in the first group and subsequently obstetric analgesia was more frequently required for them [96]. Diamorphine should be preferred over pethidine as it provides analgesia of better quality and longer duration, as mentioned by RCOG. In addition, maternal sepsis and DIC should be ruled out before the administration of regional anesthesia in order to prevent the formation of epidural or subdural abscess and hematoma, respectively.

**Postpartum thromboprophylaxis and suppression of lactation**

According to RCOG, stillbirth is not considered a risk factor for thrombosis and thus, routine thromboprophylaxis is not warranted. However, postpartum assessment for other risk factors should always be undertaken following stillbirth, as this complication is usually associated with advanced maternal age, maternal systemic diseases and increased body mass index. In case of DIC, the decision for heparin administration should be made by a hematologist.

For the inhibition of puerperal lactation, RCOG recommends the use of dopamine agonists over non-pharmacological measures and estrogens, based on two studies, which showed that bromocriptine successfully suppresses lactation in more than 90% of women without major side effects and is significantly more efficient than breast binders [97, 98]. Another study comparing the safety and efficacy of cabergoline and bromocriptine concluded that the first agent is superior, as it is equally effective in preventing puerperal lactation, while at the same time it has considerably lower rate of rebound breast activity and adverse events, as well as simpler administration schedule [99]. Notably, hypertension is a contraindication for the treatment with dopamine agonists.

**Counseling and bereavement care**

There is a general consensus among three of the reviewed guidelines (ACOG, RCOG, PSANZ) that appropriate parental counseling, communication and emotional support are required following an intrauterine death, always taking into consideration that stress and sorrow may affect how people absorb, process and respond to information. Healthcare providers should individualize the bereavement care based on parents’ personal cultural and spiritual beliefs, as they can have a significant effect on the acceptance and the recovery from such tragic events [100]. The acknowledgment of different grief responses and the recognition of parenthood are crucial in order to provide adequate support not only to the mother, but also to her relatives, as they may have already established an emotional relationship with the deceased baby. Shared decision making regarding the diagnostic and management procedure gives time to the parents to consider their options, understand their individual needs and concerns and conceptualize loss. The opportunity to see, hold, name and photograph the baby should also be provided; importantly, practitioners should avoid influencing parent’s choices (RCOG).

**Management of subsequent pregnancies**

A systematic review and meta-analysis has proven that the risk of stillbirth in future pregnancies is almost five times higher in women who experienced a stillbirth in their first pregnancy compared to those who had a previous live birth (OR: 4.77; 95% CI: 3.70–6.15) [21]; this is also highlighted by a Consensus Statement endorsed by the International Stillbirth Alliance and the SOGC [101]. Moreover, several studies have shown the association of prior fetal demise with increased risk for ischemic placental disease, cho-rioamnionitis, preterm delivery and neonatal morbidity in...
subsequent pregnancies [102–105]. Based on these data, both RCOG and ACOG recommend a more intense antenatal care to pregnant women with a previous unexplained stillbirth, although not adopting a common approach. More specifically, RCOG suggests screening all these women for gestational diabetes and serial ultrasonographic evaluation of fetal growth in the next pregnancy if the stillborn fetus was small for gestational age. ACOG recommends antenatal surveillance once or twice weekly for patients with a previous history of stillbirth that occurred at or beyond 32 weeks of gestation, starting one to two weeks before the gestational age of the prior stillbirth. Individualized care is suggested for pregnant women with a history of stillbirth before 32 weeks of gestation. ACOG also underlines the importance of eliminating the modifiable risk factors, i.e. cessation of smoking, weight loss, optimization of glycemic control and screening for acquired thrombophilias in the setting of a future pregnancy. Moreover, based on a Cochrane review, which concluded that there is insufficient evidence to influence clinical practice, the same society discourages fetal movement counting as a means of preventing stillbirth recurrence [106].

With regards to the optimal setting, mode and timing of delivery, both RCOG and ACOG agree that clinicians should take under consideration the maternal request for scheduled birth. Delivery at a specialist maternity care unit is indicated for pregnant women with previous unexplained stillbirth according to RCOG. In addition, ACOG recommends IOL or planned cesarean section at 39 weeks of gestation or earlier if maternal and fetal comorbid conditions exist in the current pregnancy. This guideline points out that early term delivery, i.e. between 37 and 38.6 weeks of gestation, may be considered in case of maternal wish and anxiety, always balancing the risks of neonatal complications with those of further continuation of pregnancy.

Finally, RCOG recommends increased vigilance for postpartum depression and anxiety during the puerperium for women with previous history of stillbirth, as these women are more vulnerable to emotional distress in future pregnancies than those without such history [107].

Conclusions

To summarize, there is an overall agreement among the reviewed guidelines that the detailed documentation of maternal history and the postmortem examination of the fetus are crucial in the investigation of an apparently unexplained stillbirth. All the medical societies agree that the determination of stillbirth’s etiology is important not only for the management of subsequent pregnancies and the prevention of recurrence, but also for the parents’ bereavement care and emotional support. They generally agree on the appropriate laboratory testing, although minor discrepancies exist regarding the thyroid function tests and the serology for viral screening. In addition, all guidelines are in favor of the genetic and microbiologic analysis of fetal and placental tissues as well as placental gross and histological examination and suggest minimally invasive procedures when autopsy is declined by the parents. RCOG and SOGC suggest screening for autoimmune diseases and testing parental blood for karyotype in selected circumstances.

On the other hand, the main issues of controversy include the definition of stillbirth, the management of subsequent pregnancies and the recommended protocols for IOL, although both ACOG and RCOG support that vaginal birth should be offered over cesarean section in case of stillbirth.

Of note, SOGC and PSANZ do not make any recommendations regarding the management of stillbirth. Finally, only RCOG provides guidance for intrapartum analgesia and antimicrobial therapy, postpartum thromboprophylaxis and suppression of puerperal lactation.

Regarding possible topics for future research, an international classification system for stillbirth, the efficacy and safety of induction of labor after a previous cesarean, the ideal follow-up, as well as the optimal psychological care for the parents, should be further investigated.

Stillbirth constitutes one of the most devastating obstetric complications despite the advances in antenatal and intrapartum care during the past several decades. It remains a significant and understudied problem that accounts for almost 50% of all perinatal deaths [80]. This descriptive review has been developed to distill the burgeoning literature and place emphasis on the importance of adopting and implementing a consistent international strategy for the optimal investigation and management of this severe complication. The ultimate goal is to achieve timely diagnosis and effective treatment of the underlying pathology, provide an individualized approach, which takes into consideration parental wishes, needs and cultural beliefs, facilitate emotional closure and prevent recurrence when possible.

Research funding: None declared.

Author contributions: Themistoklis Dagklis developed the original idea for the study, coordinated and revised the manuscript. Ioannis Tsakiridis designed, coordinated, implemented the project and submitted the article. Sonia Giouleka designed, evaluated the results and coordinated the manuscript. Apostolos Mamopoulos and Apostolos
Athanasiadis cooperated in the analysis and participated in the revision. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** Authors state no conflict of interest.

**Informed consent:** Not applicable.

**Ethical approval:** Not applicable.

**References**

1. Maslovich MM, Burke LM. Intrauterine fetal demise. Treasure Island (FL): StatPearls; 2021.
2. Confidential enquiry into maternal and child health (CEMACH) Perinatal mortality 2007: United Kingdom. London: CEMACH; 2009.
3. MacDorman MF, Gregory EC. Fetal and perinatal mortality: United States, 2013. Natl Vital Stat Rep 2015;64:1–24.
4. Fretts R. Stillbirth epidemiology, risk factors, and opportunities for stillbirth prevention. Clin Obstet Gynecol 2010;53:588–96.
5. Heazzell AEP, Siassakos D, Blencowe H, Burden C, Bhutta ZA, Cacciatoir J, et al. Stillbirths: economic and psychosocial consequences. Lancet 2016;387:604–16.
6. Balayla J, Azoulay L, Assayag J, Benjamini A, Abenhaim HA. Effect of maternal age on the risk of stillbirth: a population-based cohort study on 37 million births in the United States. Am J Perinatol 2011;28:643–50.
7. Tsakiridis I, Mamopoulos A, Athanasiadis A, Kourtis A, Dagklis T. Management of pregestational diabetes mellitus: a comparison of guidelines. J Matern Fetal Neonatal Med 2020;1:1–10. https://doi.org/10.1080/14767058.2020.1719481.
8. Tsakiridis I, Giouleka S, Mamopoulos A, Kourtis A, Athanasiadis A, Filopoulou D, et al. Diagnosis and management of gestational diabetes mellitus: an overview of national and international guidelines. Obstet Gynecol Surv 2021;76:367–81.
9. Tsakiridis I, Giouleka S, Arvanitaki A, Mamopoulos A, Giannakoulas G, Papazisis G, et al. Chronic hypertension in pregnancy: synthesis of influential guidelines. J Perinat Med 2021;49:859–72.
10. Tsakiridis I, Giouleka S, Arvanitaki A, Giannakoulas G, Papazisis G, Mamopoulos A, et al. Gestational hypertension and preeclampsia: an overview of national and international guidelines. Obstet Gynecol Surv 2021;76:613–33.
11. Tsakiridis I, Giouleka S, Kourtis A, Mamopoulos A, Athanasiadis A, Dagklis T. Thyroid disease in pregnancy: a descriptive review of guidelines. Obstet Gynecol Surv 2022;77:45–62.
12. Tsakiridis I, Mamopoulos A, Papazisis G, Petousis S, Liozidou A, Athanasiadis A, et al. Prevalence of smoking during pregnancy and associated risk factors: a cross-sectional study in Northern Greece. Eur J Publ Health 2018;28:321–5.
13. Tsakiridis I, Oikonomidou AC, Bakaloudi DR, Dagklis T, Papazisis G, Choudakis M. Substance use during pregnancy: a comparative review of major guidelines. Obstet Gynecol Surv 2021;76:634–43.
14. Cheong-See F, Schult E, Arroyo-Manzano D, Khalil A, Barrett J, Joseph KS, et al. Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis. BMJ 2016;354:i4353.
15. Tsakiridis I, Giouleka S, Mamopoulos A, Athanasiadis A, Dagklis T. Management of twin pregnancies: a comparative review of national and international guidelines. Obstet Gynecol Surv 2020;75:419–30.
16. Zavlanos A, Tsakiridis I, Chatzikalogiannis I, Athanasiadis A. Early- and late-onset intrauterine growth retardation. Donald Sch J Ultrasound Obstet Gynecol 2021;15:97–108.
17. Tsakiridis I, Mamopoulos A, Athanasiadis A, Dagklis T. Diagnosis and management of vasa previa: a comparison of 4 national guidelines. Obstet Gynecol Surv 2019;74:436–42.
18. Zhang W, Geris S, Beta J, Ramadan G, Nicolaides KH, Akolekar R. Prevention of stillbirth: impact of two-stage screening for vasa previa. Ultrasound Obstet Gynecol 2020;55:605–12.
19. Mondal D, Galloway TS, Bailey TC, Mathews F. Elevated risk of stillbirth in males: systematic review and meta-analysis of more than 30 million births. BMC Med 2014;12:220.
20. Tsakiridis I, Kasapidou E, Dagklis T, Leonida I, Leonida C, Bakaloudi DR, et al. Nutrition in pregnancy: a comparative review of major guidelines. Obstet Gynecol Surv 2020;75:692–702.
21. Lamont K, Scott NW, Jones GT, Bhattacharya S. Risk of recurrent stillbirth: systematic review and meta-analysis. BMJ 2015;350:h3080.
22. Smith GC, Shah I, White IR, Pell JP, Dobbie R. Previous preeclampsia, preterm delivery, and delivery of a small for gestational age infant and the risk of unexplained stillbirth in the second pregnancy: a retrospective cohort study, Scotland, 1992–2001. Am J Epidemiol 2007;165:194–202.
23. Goldenberg RL, Kirby R, Culhane JF. Stillbirth: a review. J Matern Fetal Neonatal Med 2004;16:79–94.
24. Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005;193:1923–35.
25. Gold KJ, Dalton VK, Schwenk TL. Hospital care for parents after perinatal death. Obstet Gynecol 2007;109:1156–66.
26. Metz TD, Berry RS, Fretts RC, Reddy UM, Turrentine MA, Obstetricians & Gynaecologists. Management of stillbirth: (replaces practice bulletin number 2010–202). Obstet Gynecol Surv 2020;75:692–702.
27. Gynecologists RCoOa. Late intrauterine fetal death and stillbirth. Green-top Guideline No. 55. UK: Royal College of Obstetricians & Gynaecologists; 2010.
28. Flenday VOJ, Gardener G, Masson V, McCowan L, Kent A, David T, et al. Clinical practice guideline for care around stillbirth and neonatal death. Brisbane, Australia: NHMRC Centre of Research Excellence in Stillbirth; 2020.Version 3.4.
29. Leduc L. No. 394-stillbirth investigation. J Obstet Gynaecol Can 2020;42:92–9.
30. (CEMACH) CEiMaCH. Perinatal mortality 2007: United Kingdom. London: CEMACH; 2009.
31. Zeit RM. Sonographic demonstration of fetal death in the absence of radiographic abnormality. Obstet Gynecol 1976;48:495–525.
32. Rand CS, Kellner KR, Revak-Lutz R, Massey JK. Parental behavior after perinatal death: twelve years of observations. J Psychosom Obstet Gynaecol 1998;19:44–8.
33. Günter HH, Scharf A, Hertel H, Hillemanns P, Wenzlaff P, Maul H. Perinatal morbidity in pregnancies of women with preconceptional and gestational diabetes mellitus in comparison with pregnancies of non-diabetic women. Results of the perinatal registry of Lower Saxony, Germany. Z Geburtshilfe Neonatol 2006;210:200–7.

34. Hansen AT, Schmidt M, Horvath-Puho E, Pedersen L, Rothman KJ, Hvas AM, et al. Preconception venous thromboembolism and placenta-mediated pregnancy complications. J Thromb Haemostasis 2015;13:1635–41.

35. Allen VM, Joseph KS, Murphy KE, Magee LA, Ohlsson A. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: a population based study. BMC Pregnancy Childbirth 2004;4:17.

36. Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019;393:899–909.

37. Parasnis H, Raje B, Hinduja IN. Relevance of plasma placenta-mediated pregnancy complications. J Thromb Haemost 2003;1:1055–61.

38. Resnik R, Creasy RK, Iams JD, Lockwood CJ, Moore T, Greene MF. Creasy and Resnik’s maternal-fetal medicine: principles and practice E-book. United States of America: Elsevier Health Sciences; 2008.

39. Nijkamp JW, Korteweg FJ, Groen H, Timmer A, Van Den Berg G, Kafetzis DA, et al. Thyroid function testing in women who had a stillbirth. Clin Endocrinol 2016;85:291–8.

40. Korteweg FJ, Erwich JJ, Timmer A, van der Meer J, Ravisé JM, Korteweg FJ, Bouman K, Erwich JJ, Timmer A, Veeger NJ, Ravise JM, et al. Stillbirths and intrauterine infection, histologic chorioamnionitis and microbiological findings. Int J Gynaecol Obstet 1996;54:115–23.

41. Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, et al. Stillbirth with group B Streptococcus disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S125–32.

42. Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol 2014;123:113–25.

43. Hoskins IA, Friedman DM, Frieden fj, Ordorica SA, Young BK. Relationship between antepartum cocaine abuse, abnormal umbilical artery Doppler velocimetry, and placental abruption. Obstet Gynecol 1991;78:279–82.

44. Kramer MS, Usher RH, Pollack R, Boyd M, Usher S. Etiologic determinants of abruptio placentae. Obstet Gynecol 1997;89:221–6.

45. Gonen R, Lavi N, Attias D, Schliamser L, Borochowitz Z, Toubi E, et al. Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death. Am J Obstet Gynecol 2005;192:742–6.

46. ACOS Practice Bulletin No. 197. Inherited thrombophilias in pregnancy. Obstet Gynecol 2018;132:e18–34.

47. Herrera CA, Heuser CC, Branch DW. Stillbirth: the impact of antiphospholipid syndrome? Lupus 2017;26:237–9.

48. Silver RM, Parker CB, Reddy UM, Goldenberg R, Coustan D, Dudley DJ, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013;122:641–57.

49. Xu J, Chen D, Duan X, Li L, Tang Y, Peng B. The association between antiphospholipid antibodies and late fetal loss: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2019;98:1523–33.

50. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060–8.

51. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Korsholm L, et al. Thyroid function testing in women who had a stillbirth. Clin Endocrinol 2016;85:291–8.

52. Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, et al. Stillbirth with group B Streptococcus disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S125–32.

53. Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol 2014;123:113–25.

54. Hoskins IA, Friedman DM, Frieden fj, Ordorica SA, Young BK. Relationship between antepartum cocaine abuse, abnormal umbilical artery Doppler velocimetry, and placental abruption. Obstet Gynecol 1991;78:279–82.

55. Kramer MS, Usher RH, Pollack R, Boyd M, Usher S. Etiologic determinants of abruptio placentae. Obstet Gynecol 1997;89:221–6.

56. Gonen R, Lavi N, Attias D, Schliamser L, Borochowitz Z, Toubi E, et al. Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death. Am J Obstet Gynecol 2005;192:742–6.

57. ACOS Practice Bulletin No. 197. Inherited thrombophilias in pregnancy. Obstet Gynecol 2018;132:e18–34.

58. Herrera CA, Heuser CC, Branch DW. Stillbirth: the impact of antiphospholipid syndrome? Lupus 2017;26:237–9.

59. Silver RM, Parker CB, Reddy UM, Goldenberg R, Coustan D, Dudley DJ, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013;122:641–57.

60. Xu J, Chen D, Duan X, Li L, Tang Y, Peng B. The association between antiphospholipid antibodies and late fetal loss: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2019;98:1523–33.

61. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060–8.

62. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Korsholm L, et al. Thyroid function testing in women who had a stillbirth. Clin Endocrinol 2016;85:291–8.

63. Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, et al. Stillbirth with group B Streptococcus disease worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65:S125–32.

64. Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol 2014;123:113–25.

65. Hoskins IA, Friedman DM, Frieden fj, Ordorica SA, Young BK. Relationship between antepartum cocaine abuse, abnormal umbilical artery Doppler velocimetry, and placental abruption. Obstet Gynecol 1991;78:279–82.

66. Kramer MS, Usher RH, Pollack R, Boyd M, Usher S. Etiologic determinants of abruptio placentae. Obstet Gynecol 1997;89:221–6.
100. Allahdadian M, Irajpour A. The role of religious beliefs in pregnancy loss. J Educ Health Promot 2015;4:99.
101. Ladhani NNN, Fockler ME, Stephens L, Barrett JFR, Heazell AEP. No. 369-Management of pregnancy subsequent to stillbirth. J Obstet Gynaecol Can 2018;40:1669–83.
102. Black M, Shetty A, Bhattacharya S. Obstetric outcomes subsequent to intrauterine death in the first pregnancy. BJOG 2008;115:269–74.
103. Pekkola M, Tikkanen M, Gissler M, Paavonen J, Stefanovic V. Stillbirth and subsequent pregnancy outcome – a cohort from a large tertiary referral hospital. J Perinat Med 2020;48:765–70.
104. Graham N, Stephens L, Johnstone ED, Heazell AEP. Can information regarding the index stillbirth determine risk of adverse outcome in a subsequent pregnancy? Findings from a single-center cohort study. Acta Obstet Gynecol Scand 2021;100:1326–35.
105. Monari F, Pedrielli G, Vergani P, Pozzi E, Mecacci F, Serena C, et al. Adverse perinatal outcome in subsequent pregnancy after stillbirth by placental vascular disorders. PLoS One 2016;11: e0155761.
106. Mangesi L, Hofmeyr GJ, Smith V, Smyth RM. Fetal movement counting for assessment of fetal wellbeing. Cochrane Database Syst Rev 2015:CD004909. https://doi.org/10.1002/14651858. CD004909.pub3.
107. Hughes PM, Turton P, Evans CD. Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study. BMJ 1999;318:1721–4.